Literature DB >> 19348713

Pseudoprogression and pseudoresponse: challenges in brain tumor imaging.

Jennifer L Clarke1, Susan Chang.   

Abstract

Assessment via MRI is an integral part of the management of primary brain tumors. However, reliance on imaging to determine treatment response is not without its pitfalls. Necrosis is a known late effect of radiation treatment of the brain that can mimic tumor recurrence. It is now appreciated that pseudoprogression, a similar effect, can occur after combined chemoradiotherapy and can occur more quickly and dramatically than after radiation alone. Although several adjunct imaging modalities are under investigation, none is yet widely accepted as being able to distinguish between true progression and pseudoprogression. Conversely, at disease progression, antiangiogenic therapies are frequently used and can have a rapid positive effect on imaging. These changes, increasingly known as "pseudoresponses," can occur immediately after initiating treatment, making accurate assessment of true tumor response difficult. This article reviews the challenges of brain tumor imaging and its use in assessment of treatment response.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19348713     DOI: 10.1007/s11910-009-0035-4

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  27 in total

1.  Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma.

Authors:  Marc C Chamberlain; Michael J Glantz; Lisa Chalmers; Alixis Van Horn; Andrew E Sloan
Journal:  J Neurooncol       Date:  2006-08-31       Impact factor: 4.130

2.  Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis.

Authors:  Mark E Mullins; Glenn D Barest; Pamela W Schaefer; Fred H Hochberg; R Gilberto Gonzalez; Michael H Lev
Journal:  AJNR Am J Neuroradiol       Date:  2005-09       Impact factor: 3.825

3.  Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements.

Authors:  L S Hu; L C Baxter; K A Smith; B G Feuerstein; J P Karis; J M Eschbacher; S W Coons; P Nakaji; R F Yeh; J Debbins; J E Heiserman
Journal:  AJNR Am J Neuroradiol       Date:  2008-12-04       Impact factor: 3.825

4.  Response criteria for phase II studies of supratentorial malignant glioma.

Authors:  D R Macdonald; T L Cascino; S C Schold; J G Cairncross
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

5.  Three-dimensional magnetic resonance spectroscopic imaging of histologically confirmed brain tumors.

Authors:  D Vigneron; A Bollen; M McDermott; L Wald; M Day; S Moyher-Noworolski; R Henry; S Chang; M Berger; W Dillon; S Nelson
Journal:  Magn Reson Imaging       Date:  2001-01       Impact factor: 2.546

6.  Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.

Authors:  Eric Raymond; Alba A Brandes; Christian Dittrich; Pierre Fumoleau; Bruno Coudert; Paul M J Clement; Marc Frenay; Roy Rampling; Roger Stupp; Johan M Kros; Michael C Heinrich; Thierry Gorlia; Denis Lacombe; Martin J van den Bent
Journal:  J Clin Oncol       Date:  2008-10-01       Impact factor: 44.544

7.  Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy.

Authors:  Yuzo Terakawa; Naohiro Tsuyuguchi; Yoshiyasu Iwai; Kazuhiro Yamanaka; Shigeaki Higashiyama; Toshihiro Takami; Kenji Ohata
Journal:  J Nucl Med       Date:  2008-04-15       Impact factor: 10.057

8.  Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

Authors:  James J Vredenburgh; Annick Desjardins; James E Herndon; Jennifer Marcello; David A Reardon; Jennifer A Quinn; Jeremy N Rich; Sith Sathornsumetee; Sridharan Gururangan; John Sampson; Melissa Wagner; Leighann Bailey; Darell D Bigner; Allan H Friedman; Henry S Friedman
Journal:  J Clin Oncol       Date:  2007-10-20       Impact factor: 44.544

9.  Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Authors:  A D Norden; G S Young; K Setayesh; A Muzikansky; R Klufas; G L Ross; A S Ciampa; L G Ebbeling; B Levy; J Drappatz; S Kesari; P Y Wen
Journal:  Neurology       Date:  2008-03-04       Impact factor: 9.910

10.  Noninvasive evaluation of malignancy of brain tumors with proton MR spectroscopy.

Authors:  H Shimizu; T Kumabe; T Tominaga; T Kayama; K Hara; Y Ono; K Sato; N Arai; S Fujiwara; T Yoshimoto
Journal:  AJNR Am J Neuroradiol       Date:  1996-04       Impact factor: 3.825

View more
  72 in total

1.  Development of a novel animal model to differentiate radiation necrosis from tumor recurrence.

Authors:  Sanath Kumar; Ali S Arbab; Rajan Jain; Jinkoo Kim; Ana C deCarvalho; Adarsh Shankar; Tom Mikkelsen; Stephen L Brown
Journal:  J Neurooncol       Date:  2012-03-10       Impact factor: 4.130

2.  Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients.

Authors:  Chul-Kee Park; JinWook Kim; Su Youn Yim; Ah Reum Lee; Jung Ho Han; Chae-Yong Kim; Sung-Hye Park; Tae Min Kim; Se-Hoon Lee; Seung Hong Choi; Seung-Ki Kim; Dong Gyu Kim; Hee-Won Jung
Journal:  Neuro Oncol       Date:  2010-11-12       Impact factor: 12.300

Review 3.  Treatment induced necrosis versus recurrent/progressing brain tumor: going beyond the boundaries of conventional morphologic imaging.

Authors:  Rajan Jain; Jayant Narang; Pia M Sundgren; David Hearshen; Sona Saksena; Jack P Rock; Jorge Gutierrez; Tom Mikkelsen
Journal:  J Neurooncol       Date:  2010-02-24       Impact factor: 4.130

4.  Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.

Authors:  Jerrold L Boxerman; Zheng Zhang; Yair Safriel; Mykol Larvie; Bradley S Snyder; Rajan Jain; T Linda Chi; A Gregory Sorensen; Mark R Gilbert; Daniel P Barboriak
Journal:  Neuro Oncol       Date:  2013-06-19       Impact factor: 12.300

Review 5.  MR imaging of neoplastic central nervous system lesions: review and recommendations for current practice.

Authors:  M Essig; N Anzalone; S E Combs; À Dörfler; S-K Lee; P Picozzi; A Rovira; M Weller; M Law
Journal:  AJNR Am J Neuroradiol       Date:  2011-10-20       Impact factor: 3.825

6.  Performance of Standardized Relative CBV for Quantifying Regional Histologic Tumor Burden in Recurrent High-Grade Glioma: Comparison against Normalized Relative CBV Using Image-Localized Stereotactic Biopsies.

Authors:  J M Hoxworth; J M Eschbacher; A C Gonzales; K W Singleton; G D Leon; K A Smith; A M Stokes; Y Zhou; G L Mazza; A B Porter; M M Mrugala; R S Zimmerman; B R Bendok; D P Patra; C Krishna; J L Boxerman; L C Baxter; K R Swanson; C C Quarles; K M Schmainda; L S Hu
Journal:  AJNR Am J Neuroradiol       Date:  2020-03-12       Impact factor: 3.825

Review 7.  Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma.

Authors:  L C Hygino da Cruz; I Rodriguez; R C Domingues; E L Gasparetto; A G Sorensen
Journal:  AJNR Am J Neuroradiol       Date:  2011-03-10       Impact factor: 3.825

8.  Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question.

Authors:  Morad Nasseri; Seymur Gahramanov; Joao Prola Netto; Rongwei Fu; Leslie L Muldoon; Csanad Varallyay; Bronwyn E Hamilton; Edward A Neuwelt
Journal:  Neuro Oncol       Date:  2014-02-11       Impact factor: 12.300

9.  New applications of nanotechnology for neuroimaging.

Authors:  G Suffredini; J E East; L M Levy
Journal:  AJNR Am J Neuroradiol       Date:  2013-03-28       Impact factor: 3.825

10.  Variability and accuracy of different software packages for dynamic susceptibility contrast magnetic resonance imaging for distinguishing glioblastoma progression from pseudoprogression.

Authors:  Zachary S Kelm; Panagiotis D Korfiatis; Ravi K Lingineni; John R Daniels; Jan C Buckner; Daniel H Lachance; Ian F Parney; Rickey E Carter; Bradley J Erickson
Journal:  J Med Imaging (Bellingham)       Date:  2015-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.